TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1916869

Group type: EXPERIMENTAL
Intervention: Two-hour infusion of amphotericin B
Number of subjects: 33

Group type: COMPARATOR
Intervention: Four-hour infusion of amphotericin B
Number of subjects: 33
Study: 7044099

Group type: EXPERIMENTAL
Intervention: CMF chemotherapy (cyclophosphamide, methotrexate, and 5‐fluorouracil)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Observation alone
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: CMF chemotherapy
Number of subjects: 34
Study: 31898389

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Multiple daily injections (MDI)
Number of subjects: 0
Study: 30865794

Group type: EXPERIMENTAL
Intervention: 1-month regimen of daily rifapentine plus isoniazid
Number of subjects: 3000

Group type: COMPARATOR
Intervention: 9-month regimen of isoniazid alone
Number of subjects: 3000
Study: 29629009

Group type: EXPERIMENTAL
Intervention: Sitting position with legs on the stool (LS group)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sitting position with legs remaining on the operating table (LT group)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study: 26063218

Group type: EXPERIMENTAL
Intervention: Custom-made foot orthoses with added support under the first metatarso-phalangeal joint
Number of subjects: 20
Study: 25099962

Group type: EXPERIMENTAL
Intervention: K90 (isometric training at long muscle lengths for 8 weeks)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: K50 (isometric training at short muscle lengths for 8 weeks)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 28
Study: 22042247

Group type: EXPERIMENTAL
Intervention: 250-μg SS (scarification of the skin)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 50-μg SS (scarification of the skin)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 100-μg ID (intradermal)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 250-μg ID (intradermal)
Number of subjects: 24
Study: 19158556

Group type: EXPERIMENTAL
Intervention: Diamond burr superficial keratectomy (DBSK)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Epithelial debridement (ED)
Number of subjects: 48
Study: 17238129

Group type: EXPERIMENTAL
Intervention: Double-blind long-term efficacy (DBLE) design
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Randomized withdrawal (RW) design
Number of subjects: 0
Study: 15190088

Group type: EXPERIMENTAL
Intervention: Prism adaptation during walking
Number of subjects: 2

Group type: COMPARATOR
Intervention: Cerebellar subjects
Number of subjects: 2

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 2
Study: 12002243

Group type: EXPERIMENTAL
Intervention: Mentoring relationships lasting a year or longer
Number of subjects: 1138

Group type: EXPERIMENTAL
Intervention: Mentoring relationships that terminated within a very short period of time
Number of subjects: 1138

Group type: EXPERIMENTAL
Intervention: Older adolescents
Number of subjects: 1138

Group type: EXPERIMENTAL
Intervention: Adolescents referred for services or with sustained emotional, sexual or physical abuse
Number of subjects: 1138

Group type: EXPERIMENTAL
Intervention: Married volunteers aged 26‐30 and those with lower incomes
Number of subjects: 1138

Group type: EXPERIMENTAL
Intervention: Dyadic factors (race, gender, relationship quality)
Number of subjects: 1138
Study: 9811072

Group type: EXPERIMENTAL
Intervention: Higher inspired oxygen (0.25 L/min higher than baseline, SaO2 >97%)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (healthy preterm infants)
Number of subjects: 16
Study: 7545214

Group type: EXPERIMENTAL
Intervention: 0.5, 1, or 1.5 micrograms/kg of rhG‐CSF daily for 4 weeks, followed by 4 weeks resting, then rhG‐CSF plus 6 MU of rIFN 3 times weekly for 4 weeks, followed by 6 MU of rIFN alone for 4 weeks, then 3 MU of rIFN for 16 weeks
Number of subjects: 15
Study: 2523644

Group type: EXPERIMENTAL
Intervention: Isradipine (1.25 to 5 mg twice daily, or 2.5 to 10 mg once daily)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Isradipine (once-daily)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Isradipine (twice-daily)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study: 506802

Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg once daily
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Atenolol 200 mg once daily
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg and 200 mg)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 37
Study: 31801173

Group type: EXPERIMENTAL
Intervention: Electronic health record (EHR) intervention
Number of subjects: 150
Study: 28724418

Group type: EXPERIMENTAL
Intervention: CTO PCI
Number of subjects: 180

Group type: COMPARATOR
Intervention: No-CTO PCI
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: CTO PCI in dysfunctional but viable segments (TEI < 50%)
Number of subjects: 180

Group type: COMPARATOR
Intervention: No-CTO PCI in dysfunctional but viable segments (TEI < 50%)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: CTO PCI with Rentrop grade 2-3 collaterals
Number of subjects: 180

Group type: COMPARATOR
Intervention: CTO PCI with Rentrop grade 0-1 collaterals
Number of subjects: 180
Study: 24863143

Group type: EXPERIMENTAL
Intervention: PEGASUS psychoeducational program
Number of subjects: 108
Study: 24225069

Group type: EXPERIMENTAL
Intervention: Adaptive pacing therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Graded exercise therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Specialist medical care
Number of subjects: 0
Study: 21457979

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 79

Group type: COMPARATOR
Intervention: Indomethacin
Number of subjects: 79
Study: 19704401

Group type: EXPERIMENTAL
Intervention: Limited sampling strategies (LSS) for estimation of mycophenolic acid (MPA) AUC(0-12) after EC-MPS administration
Number of subjects: 109
Study: 17646968

Group type: EXPERIMENTAL
Intervention: High-dose glycine (0.8 g/kg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 15142017

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate (L-CHO) diet
Number of subjects: 8

Group type: COMPARATOR
Intervention: Mixed diet
Number of subjects: 8
Study: 11583884

Group type: EXPERIMENTAL
Intervention: Postoperative peak CK-MB ratio < 5 ULN
Number of subjects: 2918

Group type: EXPERIMENTAL
Intervention: Postoperative peak CK-MB ratio >= 5 to < 10 ULN
Number of subjects: 2918

Group type: EXPERIMENTAL
Intervention: Postoperative peak CK-MB ratio >= 10 to < 20 ULN
Number of subjects: 2918

Group type: EXPERIMENTAL
Intervention: Postoperative peak CK-MB ratio >= 20 ULN
Number of subjects: 2918
Study: 9291244

Group type: EXPERIMENTAL
Intervention: Eptifibatide (INTEGRILIN)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Heparin and aspirin (current antithrombotic management)
Number of subjects: 0
Study: 7706179

Group type: EXPERIMENTAL
Intervention: Aspoxicillin 4 g tds (n = 52)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Piperacillin 4 g qds (n = 53)
Number of subjects: 105
Study: 3110654

Group type: EXPERIMENTAL
Intervention: Tiaprofenic acid (600 mg per diem b.i.d.)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Lysine acetylsalicylate (1800 mg per diem b.i.d.)
Number of subjects: 30
Study: 29389819

Group type: EXPERIMENTAL
Intervention: Self-training with an electronic audiovisual checklist app during at least 60 consecutive general anaesthesia inductions.
Number of subjects: 26

Group type: COMPARATOR
Intervention: Normal training without the electronic checklist app.
Number of subjects: 26
Study: 27175917

Group type: EXPERIMENTAL
Intervention: AORIF (Arthroscopically Assisted Open Reduction and Internal Fixation), n=37
Number of subjects: 74

Group type: COMPARATOR
Intervention: ORIF (Open Reduction and Internal Fixation), n=37
Number of subjects: 74
Study: 24472087

Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 200

Group type: COMPARATOR
Intervention: CO2 laser ablation
Number of subjects: 200
Study: 24080607

Group type: EXPERIMENTAL
Intervention: New Harmonic Scalpel (NHS)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Conventional Hemostasis (CH)
Number of subjects: 211
Study: 20886227

Group type: EXPERIMENTAL
Intervention: One-set resistance training (RT)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Three-set resistance training (RT)
Number of subjects: 8
Study: 18299305

Group type: EXPERIMENTAL
Intervention: Cold-adapted influenza vaccine, trivalent, administered intranasally, 2 doses, 35 +/- 7 days apart.
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo administered intranasally, 2 doses, 35 +/- 7 days apart.
Number of subjects: 120
Study: 16974115

Group type: EXPERIMENTAL
Intervention: Tamoxifen-associated endometrial polyps
Number of subjects: 20

Group type: COMPARATOR
Intervention: Postmenopausal polyps
Number of subjects: 20
Study: 14622082

Group type: EXPERIMENTAL
Intervention: Therapist-delivered CBT (CBT12)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Therapist-delivered CBT (CBT6)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Computer-augmented CBT (CBT6-CA)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 186
Study: 10998460

Group type: EXPERIMENTAL
Intervention: High saturated fat diet (21% energy from saturated fat, 3% energy from polyunsaturated fat)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: High polyunsaturated fat diet (11% energy as saturated fat, 10% energy as polyunsaturated fat)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Dietary compliance measures (changes in reported saturated and polyunsaturated fat intake)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Triglyceride linoleate (reflecting polyunsaturated fat intake)
Number of subjects: 55
Study: 8726156

Group type: EXPERIMENTAL
Intervention: Nebulized flunisolide
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 1431312

Group type: EXPERIMENTAL
Intervention: recombinant human interferon‐beta (rHuIFN‐beta)
Number of subjects: 12

Group type: COMPARATOR
Intervention: natural IFN‐beta
Number of subjects: 12
Study: 3888864

Group type: EXPERIMENTAL
Intervention: S-adenosylmethionine (SAMe) 400 mg thrice daily for 30 days
Number of subjects: 150

Group type: COMPARATOR
Intervention: Ibuprofen 400 mg thrice daily for 30 days
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: S-adenosylmethionine (SAMe)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Routine laboratory tests
Number of subjects: 150
Study: 31308274

Group type: EXPERIMENTAL
Intervention: Plastic tongue scraper
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metal tongue scraper
Number of subjects: 0

Group type: COMPARATOR
Intervention: Manual toothbrush with tongue scraper
Number of subjects: 0
Study: 30570860

Group type: EXPERIMENTAL
Intervention: Combination of crystalloids and a small colloid dose
Number of subjects: 80

Group type: COMPARATOR
Intervention: Only crystalloid solutions
Number of subjects: 80
Study: 26659366

Group type: EXPERIMENTAL
Intervention: Capecitabine 2000 mg/m² day 1-14 (ARM A)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Capecitabine 2000 mg/m² day 1-14 + mitomycin C 6 mg/m² day 1 (ARM B)
Number of subjects: 57
Study: 24661196

Group type: EXPERIMENTAL
Intervention: 300 mg Coenzyme Q10 per day
Number of subjects: 23

Group type: COMPARATOR
Intervention: No intervention (controls)
Number of subjects: 23
Study: 22809314

Group type: EXPERIMENTAL
Intervention: Stabilisation splint treatment
Number of subjects: 80

Group type: COMPARATOR
Intervention: Counselling and masticatory muscle exercises (Control)
Number of subjects: 80
Study: 20545388

Group type: EXPERIMENTAL
Intervention: Levodopa with CM-URINE condition
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Levodopa with CM-ATTEND condition
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Levodopa with CM-MEDICATION condition
Number of subjects: 136

Group type: COMPARATOR
Intervention: Placebo with CM-URINE condition
Number of subjects: 136

Group type: COMPARATOR
Intervention: Placebo with CM-ATTEND condition
Number of subjects: 136

Group type: COMPARATOR
Intervention: Placebo with CM-MEDICATION condition
Number of subjects: 136
Study: 17921396

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (VAS) 50,000 IU
Number of subjects: 2710

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2710
Study: 16047057

Group type: EXPERIMENTAL
Intervention: Aspirin (300 mg daily for 12 weeks)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 12394931

Group type: EXPERIMENTAL
Intervention: Ultrasound examination
Number of subjects: 12
Study: 10420471

Group type: EXPERIMENTAL
Intervention: Bemithyl (bemactor)
Number of subjects: 0
Study: 7484965

Group type: EXPERIMENTAL
Intervention: 0.0155‐inch diameter multiple‐stranded stainless steel wire (Dentaflex)
Number of subjects: 74

Group type: COMPARATOR
Intervention: 0.014‐inch diameter nickel‐titanium alloy wire (NiTi)
Number of subjects: 74
Study: 2278337

Group type: EXPERIMENTAL
Intervention: Lormetazepam 1 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Midazolam 15 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Zopiclone 7.5 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (reference values)
Number of subjects: 60
Study: 373105

Group type: EXPERIMENTAL
Intervention: Pirenzepine (75 mg/day)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Cimetidine (1 g/day)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 31483448

Group type: COMPARATOR
Intervention: Gemcitabine
Number of subjects: 730

Group type: EXPERIMENTAL
Intervention: Gemcitabine plus capecitabine
Number of subjects: 730

Group type: EXPERIMENTAL
Intervention: Local recurrence
Number of subjects: 730

Group type: EXPERIMENTAL
Intervention: Distant recurrence
Number of subjects: 730

Group type: EXPERIMENTAL
Intervention: Distant-only recurrence
Number of subjects: 730

Group type: EXPERIMENTAL
Intervention: Local with distant recurrence
Number of subjects: 730

Group type: EXPERIMENTAL
Intervention: Only local recurrence
Number of subjects: 730
Study: 28113040

Group type: EXPERIMENTAL
Intervention: Endoscopic procedure (group B)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Open procedure (group A)
Number of subjects: 52
Study: 26456726

Group type: EXPERIMENTAL
Intervention: Exposure to leprosy patients in the workplace
Number of subjects: 280
Study: 23896332

Group type: EXPERIMENTAL
Intervention: 6MWT on a 10m course
Number of subjects: 45

Group type: COMPARATOR
Intervention: 6MWT on a 30m course
Number of subjects: 45
Study: 20930643

Group type: EXPERIMENTAL
Intervention: PEG‐IFNα‐2b plus ribavirin therapy
Number of subjects: 4913

Group type: EXPERIMENTAL
Intervention: PEG‐IFNα‐2b plus ribavirin therapy continued post-seizure
Number of subjects: 4913
Study: 19343014

Group type: EXPERIMENTAL
Intervention: High-protein diet (HP): 25% protein
Number of subjects: 95

Group type: COMPARATOR
Intervention: Standard protein diet (SP): 15% protein
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Both diets (HP and SP)
Number of subjects: 95
Study: 16704650

Group type: EXPERIMENTAL
Intervention: Folic acid (FA) 5 mg daily
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 15100668

Group type: EXPERIMENTAL
Intervention: Multifaceted intervention program including avoidance of house dust mite, pet allergen, and environmental tobacco smoke; encouragement of breast-feeding with formula supplementation; delayed introduction of solid foods
Number of subjects: 545

Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 545

Group type: EXPERIMENTAL
Intervention: Multifaceted intervention program
Number of subjects: 545

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 545
Study: 11841194

Group type: EXPERIMENTAL
Intervention: Clindagel (clindamycin phosphate 1% gel), administered once daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cleocin T (slightly different gel formulation), indicated for twice-daily use
Number of subjects: 0
Study: 9728526

Group type: EXPERIMENTAL
Intervention: Valaciclovir 250 mg once daily
Number of subjects: 1479

Group type: EXPERIMENTAL
Intervention: Valaciclovir 500 mg once daily
Number of subjects: 1479

Group type: EXPERIMENTAL
Intervention: Valaciclovir 1 g once daily
Number of subjects: 1479

Group type: EXPERIMENTAL
Intervention: Valaciclovir 250 mg twice daily
Number of subjects: 1479

Group type: EXPERIMENTAL
Intervention: Acyclovir 400 mg twice daily
Number of subjects: 1479

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1479
Study: 8031815

Group type: EXPERIMENTAL
Intervention: Education plus exercise
Number of subjects: 9

Group type: COMPARATOR
Intervention: Education alone
Number of subjects: 9
Study: 2738998

Group type: EXPERIMENTAL
Intervention: Intranasal beclomethasone spray
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo spray
Number of subjects: 0
Study: 15571711

Group type: EXPERIMENTAL
Intervention: Comprehensive, intensive treatment from 3 to 12 months post-stroke
Number of subjects: 18
Study: 31834164

Group type: EXPERIMENTAL
Intervention: AR-based portable navigation system
Number of subjects: 46

Group type: COMPARATOR
Intervention: Conventional freehand technique (mechanical alignment guide)
Number of subjects: 46
Study: 31079137

Group type: EXPERIMENTAL
Intervention: Customized 3D printed insoles
Number of subjects: 80

Group type: COMPARATOR
Intervention: Prefabricated insoles
Number of subjects: 80
Study: 28096758

Group type: EXPERIMENTAL
Intervention: PWS (pre-workout dietary supplement)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: PWS + S (pre-workout dietary supplement with p-synephrine)
Number of subjects: 25

Group type: COMPARATOR
Intervention: PLA (placebo)
Number of subjects: 25
Study: 26086833

Group type: EXPERIMENTAL
Intervention: Iminoral
Number of subjects: 221

Group type: COMPARATOR
Intervention: Neoral
Number of subjects: 221
Study: 24300486

Group type: EXPERIMENTAL
Intervention: Iloprost
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alprostadil
Number of subjects: 0
Study: 22107734

Group type: EXPERIMENTAL
Intervention: α-lipoic acid supplementation (1 gram per day) plus exercise training (30 minutes a day, 5 days per week for 12 weeks)
Number of subjects: 24

Group type: COMPARATOR
Intervention: α-lipoic acid supplementation only (1 gram per day for 12 weeks)
Number of subjects: 24
Study: 20441061

Group type: EXPERIMENTAL
Intervention: Metformin (500 mg TDS) until the end of 8 weeks gestation (Group B)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Metformin (500 mg TDS) until the end of 12 weeks gestation (Group C)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Metformin (500 mg TDS) stopped immediately after diagnosis of pregnancy (Group A)
Number of subjects: 75
Study: 17022766

Group type: EXPERIMENTAL
Intervention: Oral nystatin prophylaxis administered three times a day to all neonates (Group B)
Number of subjects: 3991

Group type: EXPERIMENTAL
Intervention: Oral nystatin prophylaxis for yeast carriers (Group A1)
Number of subjects: 3991

Group type: EXPERIMENTAL
Intervention: Oral nystatin prophylaxis for non-yeast carriers (Group A2)
Number of subjects: 3991

Group type: EXPERIMENTAL
Intervention: Oral nystatin prophylaxis (Groups A1 and A2 combined)
Number of subjects: 3991

Group type: COMPARATOR
Intervention: Control group (Group B)
Number of subjects: 3991
Study: 15333855

Group type: EXPERIMENTAL
Intervention: Therapeutic continuous positive airways pressure (CPAP) for 1 month
Number of subjects: 220

Group type: COMPARATOR
Intervention: Subtherapeutic continuous positive airways pressure (CPAP) for 1 month
Number of subjects: 220
Study: 10947033

Group type: EXPERIMENTAL
Intervention: Slow-release caffeine 150 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Slow-release caffeine 300 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Slow-release caffeine 600 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 9709282

Group type: EXPERIMENTAL
Intervention: Screening mammography
Number of subjects: 8
Study: 8279669

Group type: EXPERIMENTAL
Intervention: Aftercare
Number of subjects: 0

Group type: COMPARATOR
Intervention: No additional treatment
Number of subjects: 0
Study: 2894787

Group type: EXPERIMENTAL
Intervention: 70 micrograms.kg‐1 fazadinium
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 70 micrograms.kg‐1 pancuronium
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 2,500 micrograms.kg‐1 gallamine
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 450 micrograms.kg‐1 d‐tubocurarine
Number of subjects: 36
Study: 29251282

Group type: EXPERIMENTAL
Intervention: D2 receptor antagonist amisulpride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28704263

Group type: EXPERIMENTAL
Intervention: Facebook advertising
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional recruitment methods
Number of subjects: 0
Study: 26069111

Group type: EXPERIMENTAL
Intervention: PAC group (n=29)
Number of subjects: 58

Group type: COMPARATOR
Intervention: NICOM group (n=29)
Number of subjects: 58
Study: 21904194

Group type: COMPARATOR
Intervention: Group A: 2.5 mL of 0.5% hyperbaric bupivacaine + 1 mL sterile water intrathecally
Number of subjects: 75

Group type: COMPARATOR
Intervention: Group B: 2.5 mL of 0.5% hyperbaric bupivacaine + 1 mL (200 μg) nalbuphine intrathecally
Number of subjects: 75

Group type: COMPARATOR
Intervention: Group C: 2.5 mL of 0.5% hyperbaric bupivacaine + 1 mL (400 μg) nalbuphine intrathecally
Number of subjects: 75
Study: 22001132

Group type: EXPERIMENTAL
Intervention: Concurrent Training 1 (CT1)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Concurrent Training 2 (CT2)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control Session (CS)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Zinc
Number of subjects: 10
Study: 18982918

Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alendronate (once-weekly regimen)
Number of subjects: 0
Study: 16412443

Group type: EXPERIMENTAL
Intervention: MS specialist nurse programme
Number of subjects: 616

Group type: COMPARATOR
Intervention: Control group (no MS nurse posts)
Number of subjects: 616
Study: 12887480

Group type: EXPERIMENTAL
Intervention: Dutasteride 0.5 mg once daily for 2 years
Number of subjects: 4325

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4325

Group type: EXPERIMENTAL
Intervention: Dutasteride
Number of subjects: 4325